Calidi Biotherapeutics (CLDI) Total Liabilities (2021 - 2026)

Calidi Biotherapeutics has reported Total Liabilities for 6 years, with the latest figure at $4.1 million in Q2 2026.

• On a quarterly basis, Total Liabilities fell 44.04% year-over-year to $4.1 million in Q2 2026; TTM through Jun 2026 was $4.1 million, a 44.04% decrease from a year earlier, with the FY2025 full-year figure at $5.1 million, down 58.26% from the prior year.
• Total Liabilities was $4.1 million for Q2 2026 at Calidi Biotherapeutics, down from $5.1 million in the prior quarter.
• The five-year high for Total Liabilities was $43.4 million in Q4 2022, with the low at $4.1 million in Q2 2026.
• Average Total Liabilities over 5 years is $13.9 million, with a median of $12.2 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities jumped 169.58% in 2024, then slumped 64.67% in 2025.
• Over 5 years, Total Liabilities stood at $43.4 million in 2022, then sank by 57.97% to $18.3 million in 2023, then tumbled by 33.09% to $12.2 million in 2024, then plunged by 58.26% to $5.1 million in 2025, then retreated by 20.15% to $4.1 million in 2026.
• The last three Total Liabilities figures came in at $4.1 million (Q2 2026), $5.1 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.